3 min read
Business

Moderna’s Stock Soars as Oppenheimer Upgrades Rating to “Buy

Moderna Inc., a groundbreaking biotechnology company, experienced a dramatic surge in its stock price following a recent upgrade by Oppenheimer. The esteemed investment firm raised its rating on Moderna from “Hold” to “Buy,” citing optimistic expectations for the company’s future growth and potential breakthroughs in the healthcare sector.